DrugPatentWatch Database Preview

Valeant Company Profile

VALEANT has one hundred and twenty-five approved drugs.

There are forty US patents protecting VALEANT drugs.

US Patents:	40
Tradenames:	102
Ingredients:	80
NDAs:	125
Patent Litigation for Valeant:	See patent lawsuits for Valeant

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharms Llc	MESTINON	pyridostigmine bromide	TABLET;ORAL	009829-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Valeant Pharms North	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-001	Apr 23, 2008		RX	Yes	No	7,585,897	➤ Sign Up	Y			➤ Sign Up
Valeant Pharm Intl	MESTINON	pyridostigmine bromide	INJECTABLE;INJECTION	009830-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Valeant Pharms Llc	MACUGEN	pegaptanib sodium	INJECTABLE;INTRAVITREAL	021756-001	Dec 17, 2004	6,426,335	➤ Sign Up
Valeant Pharms Intl	APRISO	mesalamine	CAPSULE, EXTENDED RELEASE;ORAL	022301-001	Oct 31, 2008	8,337,886	➤ Sign Up
Valeant Pharms North	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-002	Sep 11, 1995	5,529,791	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	200 mg	➤ Subscribe	2007-03-28
➤ Subscribe	Extended-release Tablets	9 mg	➤ Subscribe	2013-03-11
➤ Subscribe	Tablets	1.1 g	➤ Subscribe	2013-11-05
➤ Subscribe	Rectal Gel	2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL	➤ Subscribe	2004-03-23
➤ Subscribe	Rectal Gel	5 mg/mL, 2mL pre-filled syringe	➤ Subscribe	2008-12-23
➤ Subscribe	Gel	0.04%	➤ Subscribe	2010-12-20
➤ Subscribe	Extended-release Tablets	348 mg	➤ Subscribe	2009-09-24
➤ Subscribe	Extended-release Tablets	420 mg	➤ Subscribe	2005-04-25
➤ Subscribe	Capsules	75 mg	➤ Subscribe	2011-06-06
➤ Subscribe	Extended-release Tablets	100 mg	➤ Subscribe	2007-01-08
➤ Subscribe	Extended-release Tablets	300 mg	➤ Subscribe	2007-09-25
➤ Subscribe	Extended-release Capsules	0.375 g	➤ Subscribe	2012-04-03
➤ Subscribe	Cream	0.5%	➤ Subscribe	2011-07-29
➤ Subscribe	Rectal Gel	5 mg/mL, 4mL pre-filled syringe	➤ Subscribe	2008-12-08
➤ Subscribe	Gel	0.1%	➤ Subscribe	2010-07-08
➤ Subscribe	Extended-release Tablets	174 mg	➤ Subscribe	2009-09-28
➤ Subscribe	Extended-release Tablets	120 mg, 180 mg, 240 mg, 300 mg and 360 mg	➤ Subscribe	2005-08-30
➤ Subscribe	Extended-release Tablets	522 mg	➤ Subscribe	2009-12-24
➤ Subscribe	Extended-release Tablets	150 mg and 300 mg	➤ Subscribe	2004-09-21
➤ Subscribe	For Inhalation Solution	6 gm/vial	➤ Subscribe	2014-05-22

Patent Number	Expiration Date
➤ Sign Up	➤ Sign Up

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB06/021	United Kingdom	➤ Sign Up	PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
/1997	Austria	➤ Sign Up	PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827
2006004	Lithuania	➤ Sign Up	PRODUCT NAME: PEGAPTANIBUM; REG. NO/DATE: EU/1/05/325/001 20060131
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.